Abstract
Background: Flow cytometry is a well-accepted approach for immune profiling; however, its value is restricted by the limited number of markers that can be analyzed simultaneously. Mass cytometry/CyTOF offers broad-scale immune characterization integrating large number of parameters. While partial blood phenotyping was reported in atopic dermatitis (AD), patients’ comprehensive profiling, critical for leveraging new targeted treatments, is not available. IL-21 may be involved in inflammatory skin diseases but its role in AD is not well established. Methods: We studied T-cell polarization in the blood of 20 moderate-to-severe AD and 15 controls. Using CyTOF and an unsupervised analysis, we measured the frequencies and mean metal intensities of activated polar CD4+/CD8+ T-cell subsets. Immunohistochemistry, immunofluorescence, and qRT-PCR were used to analyze skin samples. Results: Examining 24 surface, intracellular markers, and transcription factors, we identified six CD4+ and five CD8+ T-cell metaclusters. A CD4+ skin-homing IL-13+monocytokine and a novel IL-13+IL-21+ multicytokine metaclusters were increased in AD vs. controls (p <.01). While IL-13 signature characterized both clusters, levels were significantly higher in the IL-21+ group. Both clusters correlated with AD severity (r = 0.49, p =.029). Manual gating corroborated these results and identified additional multicytokine subsets in AD. Immunohistochemistry and immunofluorescence, validated by mRNA expression, displayed significantly increasedIL-21 counts and colocalization with IL-13/IL-4R in AD skin. Conclusion: A multicytokine signature characterizes moderate-to-severe AD, possibly explaining partial therapeutic responses to one cytokine targeting, particularly in severe patients. Prominent IL-21 signature in blood and skin hints for a potential pathogenic role of IL-21 in AD.
Original language | English |
---|---|
Pages (from-to) | 3080-3093 |
Number of pages | 14 |
Journal | Allergy: European Journal of Allergy and Clinical Immunology |
Volume | 76 |
Issue number | 10 |
DOIs | |
State | Published - Oct 2021 |
Keywords
- CyTOF
- IL-13
- IL-21
- atopic dermatitis
- biomarkers
- mass cytometry
Access to Document
Fingerprint
Dive into the research topics of 'High-dimensional analysis defines multicytokine T-cell subsets and supports a role for IL-21 in atopic dermatitis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, No. 10, 10.2021, p. 3080-3093.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - High-dimensional analysis defines multicytokine T-cell subsets and supports a role for IL-21 in atopic dermatitis
AU - Czarnowicki, Tali
AU - Kim, Hyun Je
AU - Villani, Axel P.
AU - Glickman, Jacob
AU - Duca, Ester Del
AU - Han, Joseph
AU - Pavel, Ana B.
AU - Lee, Brian H.
AU - Rahman, Adeeb H.
AU - Merad, Miriam
AU - Krueger, James G.
AU - Guttman-Yassky, Emma
N1 - Funding Information: Dr. Czarnowicki has nothing to disclose. Dr. Kim has nothing to disclose. Dr. Villani has nothing to disclose. Mr. Glickman has nothing to disclose. Dr. Del Duca has nothing to disclose. Mr. Han has nothing to disclose. Dr. Pavel has nothing to disclose. Mr. Lee has nothing to disclose. Dr. Rahman has nothing to disclose. Dr. Merad reports personal fees and other from Compugen Inc., personal fees and other from Innate Pharma Inc., personal fees and other from Morphic Therapeutic, personal fees and other from Myeloid Therapeutics, personal fees and other from Celsius Therapeutics, grants from Genentech Inc., grants from Regeneron Inc., grants from Boerhinger Ingelheim Inc., grants from Takeda Inc., during the conduct of the study. Dr. Krueger reports personal fees and other from Novartis, personal fees and other from Pfizer, personal fees and other from Amgen, personal fees and other from Lilly, personal fees and other from Boehringer, other from Innovaderm, personal fees and other from BMS, personal fees from BiogenIdec, personal fees and other from Janssen, personal fees and other from AbbVie, other from Paraxel, personal fees and other from Leo Pharma, personal fees from ESCALIER, other from Vitae, other from Akros, personal fees from Valeant, other from Regeneron, personal fees and other from Allergan, other from Novan, personal fees from Aurigene, other from BiogenMA, personal fees and other from Sienna, personal fees and other from UCB, personal fees and other from Allergan, personal fees from Asana, personal fees and other from Celgene, personal fees from Nimbus, personal fees from Menlo, other from Botanix, other from Incyte, other from Avillion, personal fees from Aristea, personal fees from Sanofi, personal fees from Sun Pharma, personal fees from Almirall, personal fees from Arena, other from Exicure, personal fees from Ventyx, personal fees from Aclaris, personal fees from Galapagos, during the conduct of the study. Dr. Guttman‐Yassky reports grants and personal fees from AbbVie, grants and personal fees from Almirall, personal fees from Amgen, grants from AnaptysBio, grants and personal fees from Asana Biosciences, grants and personal fees from Boehringer‐Ingelheim, personal fees from Cara Therapeutics, grants and personal fees from Celgene, personal fees from Concert, personal fees from DBV, grants and personal fees from Dermavant, grants and personal fees from Dermira, grants and personal fees from DS Biopharma, personal fees from EMD Serono, personal fees from Escalier, grants and personal fees from Galderma, grants and personal fees from Ichnos Sciences, personal fees from Incyte, grants from Innovaderm, grants from Janssen Biotech, grants from Kiniska, grants and personal fees from Kyowa Kirin, grants and personal fees from LEO Pharmaceuticals, grants and personal fees from Lilly, personal fees from Mitsubishi Tanabe, personal fees from Novan, grants and personal fees from Pfizer, grants from Ralexar, personal fees from RAPT Therapeutics, grants and personal fees from Regeneron, personal fees from Sanofi, grants and personal fees from Sienna Biopharmaceuticals, grants from UCB, grants and personal fees from Union Therapeutics, personal fees from Pandion Therapeutics, personal fees from AstraZeneca Biopharmaceuticals, personal fees from Target PharmaSolutions, outside the submitted work. We thank the European Academy of Dermatology and Venereology and the French Society of Dermatology for scholarship grants awarded to APV. Funding Information: Dr. Czarnowicki has nothing to disclose. Dr. Kim has nothing to disclose. Dr. Villani has nothing to disclose. Mr. Glickman has nothing to disclose. Dr. Del Duca has nothing to disclose. Mr. Han has nothing to disclose. Dr. Pavel has nothing to disclose. Mr. Lee has nothing to disclose. Dr. Rahman has nothing to disclose. Dr. Merad reports personal fees and other from Compugen Inc., personal fees and other from Innate Pharma Inc., personal fees and other from Morphic Therapeutic, personal fees and other from Myeloid Therapeutics, personal fees and other from Celsius Therapeutics, grants from Genentech Inc., grants from Regeneron Inc., grants from Boerhinger Ingelheim Inc., grants from Takeda Inc., during the conduct of the study. Dr. Krueger reports personal fees and other from Novartis, personal fees and other from Pfizer, personal fees and other from Amgen, personal fees and other from Lilly, personal fees and other from Boehringer, other from Innovaderm, personal fees and other from BMS, personal fees from BiogenIdec, personal fees and other from Janssen, personal fees and other from AbbVie, other from Paraxel, personal fees and other from Leo Pharma, personal fees from ESCALIER, other from Vitae, other from Akros, personal fees from Valeant, other from Regeneron, personal fees and other from Allergan, other from Novan, personal fees from Aurigene, other from BiogenMA, personal fees and other from Sienna, personal fees and other from UCB, personal fees and other from Allergan, personal fees from Asana, personal fees and other from Celgene, personal fees from Nimbus, personal fees from Menlo, other from Botanix, other from Incyte, other from Avillion, personal fees from Aristea, personal fees from Sanofi, personal fees from Sun Pharma, personal fees from Almirall, personal fees from Arena, other from Exicure, personal fees from Ventyx, personal fees from Aclaris, personal fees from Galapagos, during the conduct of the study. Dr. Guttman-Yassky reports grants and personal fees from AbbVie, grants and personal fees from Almirall, personal fees from Amgen, grants from AnaptysBio, grants and personal fees from Asana Biosciences, grants and personal fees from Boehringer-Ingelheim, personal fees from Cara Therapeutics, grants and personal fees from Celgene, personal fees from Concert, personal fees from DBV, grants and personal fees from Dermavant, grants and personal fees from Dermira, grants and personal fees from DS Biopharma, personal fees from EMD Serono, personal fees from Escalier, grants and personal fees from Galderma, grants and personal fees from Ichnos Sciences, personal fees from Incyte, grants from Innovaderm, grants from Janssen Biotech, grants from Kiniska, grants and personal fees from Kyowa Kirin, grants and personal fees from LEO Pharmaceuticals, grants and personal fees from Lilly, personal fees from Mitsubishi Tanabe, personal fees from Novan, grants and personal fees from Pfizer, grants from Ralexar, personal fees from RAPT Therapeutics, grants and personal fees from Regeneron, personal fees from Sanofi, grants and personal fees from Sienna Biopharmaceuticals, grants from UCB, grants and personal fees from Union Therapeutics, personal fees from Pandion Therapeutics, personal fees from AstraZeneca Biopharmaceuticals, personal fees from Target PharmaSolutions, outside the submitted work. We thank the European Academy of Dermatology and Venereology and the French Society of Dermatology for scholarship grants awarded to APV. Publisher Copyright: © 2021 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
PY - 2021/10
Y1 - 2021/10
N2 - Background: Flow cytometry is a well-accepted approach for immune profiling; however, its value is restricted by the limited number of markers that can be analyzed simultaneously. Mass cytometry/CyTOF offers broad-scale immune characterization integrating large number of parameters. While partial blood phenotyping was reported in atopic dermatitis (AD), patients’ comprehensive profiling, critical for leveraging new targeted treatments, is not available. IL-21 may be involved in inflammatory skin diseases but its role in AD is not well established. Methods: We studied T-cell polarization in the blood of 20 moderate-to-severe AD and 15 controls. Using CyTOF and an unsupervised analysis, we measured the frequencies and mean metal intensities of activated polar CD4+/CD8+ T-cell subsets. Immunohistochemistry, immunofluorescence, and qRT-PCR were used to analyze skin samples. Results: Examining 24 surface, intracellular markers, and transcription factors, we identified six CD4+ and five CD8+ T-cell metaclusters. A CD4+ skin-homing IL-13+monocytokine and a novel IL-13+IL-21+ multicytokine metaclusters were increased in AD vs. controls (p <.01). While IL-13 signature characterized both clusters, levels were significantly higher in the IL-21+ group. Both clusters correlated with AD severity (r = 0.49, p =.029). Manual gating corroborated these results and identified additional multicytokine subsets in AD. Immunohistochemistry and immunofluorescence, validated by mRNA expression, displayed significantly increasedIL-21 counts and colocalization with IL-13/IL-4R in AD skin. Conclusion: A multicytokine signature characterizes moderate-to-severe AD, possibly explaining partial therapeutic responses to one cytokine targeting, particularly in severe patients. Prominent IL-21 signature in blood and skin hints for a potential pathogenic role of IL-21 in AD.
AB - Background: Flow cytometry is a well-accepted approach for immune profiling; however, its value is restricted by the limited number of markers that can be analyzed simultaneously. Mass cytometry/CyTOF offers broad-scale immune characterization integrating large number of parameters. While partial blood phenotyping was reported in atopic dermatitis (AD), patients’ comprehensive profiling, critical for leveraging new targeted treatments, is not available. IL-21 may be involved in inflammatory skin diseases but its role in AD is not well established. Methods: We studied T-cell polarization in the blood of 20 moderate-to-severe AD and 15 controls. Using CyTOF and an unsupervised analysis, we measured the frequencies and mean metal intensities of activated polar CD4+/CD8+ T-cell subsets. Immunohistochemistry, immunofluorescence, and qRT-PCR were used to analyze skin samples. Results: Examining 24 surface, intracellular markers, and transcription factors, we identified six CD4+ and five CD8+ T-cell metaclusters. A CD4+ skin-homing IL-13+monocytokine and a novel IL-13+IL-21+ multicytokine metaclusters were increased in AD vs. controls (p <.01). While IL-13 signature characterized both clusters, levels were significantly higher in the IL-21+ group. Both clusters correlated with AD severity (r = 0.49, p =.029). Manual gating corroborated these results and identified additional multicytokine subsets in AD. Immunohistochemistry and immunofluorescence, validated by mRNA expression, displayed significantly increasedIL-21 counts and colocalization with IL-13/IL-4R in AD skin. Conclusion: A multicytokine signature characterizes moderate-to-severe AD, possibly explaining partial therapeutic responses to one cytokine targeting, particularly in severe patients. Prominent IL-21 signature in blood and skin hints for a potential pathogenic role of IL-21 in AD.
KW - CyTOF
KW - IL-13
KW - IL-21
KW - atopic dermatitis
KW - biomarkers
KW - mass cytometry
UR - http://www.scopus.com/inward/record.url?scp=85104826833&partnerID=8YFLogxK
U2 - 10.1111/all.14845
DO - 10.1111/all.14845
M3 - Article
C2 - 33818809
AN - SCOPUS:85104826833
SN - 0105-4538
VL - 76
SP - 3080
EP - 3093
JO - Allergy: European Journal of Allergy and Clinical Immunology
JF - Allergy: European Journal of Allergy and Clinical Immunology
IS - 10
ER -